Effect of Insulin Degludec/Insulin Aspart Combined with Fenofibrate on Visceral Fat Index in Obese Type 2 Diabetes Patients
Liu Xiaolong
Du Jia
Abstract：Objective:To investigate the effect of insulin degludec/insulin aspart combined with fenofibrate on visceral fat index in obese type 2 diabetes patients.Methods:136 obese type 2 diabetes patients admitted to the hospital from September 2022 to September 2023 were divided into the control group(68 cases)and the observation group(68 cases)according to the random number table method.Both groups received routine exercise and dietary control.The control group received treatment with insulin degludec/insulin aspart combined with simvastatin,while the observation group received treatment with insulin degludec/insulin aspart combined with fenofibrate、The treatment lasted for 1 month.The indexes of glucose and lipid metabolism,insulin related indexes and visceral fat index were compared between the two groups,and the incidence of adverse reactions during treatment was counted.Results:1 month after treatment,the levels of total cholesterol,glycated hemoglobin,low-density lipoprotein cholesterol,2-hour postprandial blood glucose,triglycerides and fasting blood glucose in the observation group were all lower than those in the control group,while the level of high-density lipoprotein cholesterol was higher than that in the control group.The differences were all statistically significant(t=4.866,2.392,2.559,3.130,4.059,6.397,2.698;P＜0.05).The insulin resistance index level of patients in the observation group was higher than that in the control group,while the glucagon-like peptide-1 and fasting insulin levels were lower than those in the control group.The differences were statistically significant(t=8.173,6.864,8.947;P＜0.05).The visceral fat index of both groups of patients was lower than that before treatment,and the index of the observation group was lower than that of the control group.The difference was statistically significant(t=6.144,3.317,3.308;P＜0.05).Conclusion:Insulin degludec/insulin aspart combined with fenofibrate can improve the glucose and lipid metabolism indexes and insulin related indexes in obese type 2 diabetes patients,reduce the visceral fat index of patients,and will not increase adverse reactions.
Keywords：Insulin degludec/insulin aspartFenofibrateObese type 2 diabetesVisceral fat index
Publication Date：2025-07-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1735-1737,1741 )